hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06372821 id: 158160 briefTitle: A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK acronym: NIO-SILK overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-02 date: 2025-08 date: 2024-04-18 date: 2024-04-18 name: University College, London class: OTHER name: Washington University School of Medicine name: University of Washington name: Alzheimer's Association name: Sigrid Rausing Trust briefSummary: This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells. In Alzheimer's disease (AD) it builds up in the brain, causing damage. Abnormal tau proteins cling to each other forming 'tangles' inside nerve cells, which interfere with how the nerve cells work, and eventually die. This is what causes the symptoms of dementia. It is thought that NIO752 reduces production of tau. conditions: Alzheimer Disease conditions: Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder) conditions: Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder) conditions: Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder) studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 10 type: ESTIMATED name: NIO752 name: Placebo measure: Tau synthesis rate inhibition in individuals with sporadic AD and ADAD measure: Compare efficacy of knockdown of tau production in sporadic AD and ADAD by measuring the synthesis rate of tau by determining the ratio of labelled to unlabeled tau (tracer to tracee ratio) in serial cerebrospinal fluid samples. measure: Number of participants with adverse events [safety and tolerability] measure: Comparison of number of Adverse Events reported between participants receiving one dose of NIO752 versus those receiving two doses of NIO752. measure: Compare rates of tau synthesis and clearance in sporadic AD and ADAD measure: Determine CSF tau concentration to tau production relationships in humans sex: ALL minimumAge: 21 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06372808 id: 2022/118 briefTitle: The Effect of Plyometric Training in Freestyle Adolescent Wrestlers overallStatus: RECRUITING date: 2023-10-01 date: 2024-06-18 date: 2024-09-15 date: 2024-04-18 date: 2024-04-19 name: Hasan Kalyoncu University class: OTHER briefSummary: This study aims to determine the effect of plyometric exercises on physical fitness parameters in freestyle adolescent wrestlers. conditions: Physical Fitness conditions: Power studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 40 type: ESTIMATED name: The Plyometric Exercise name: The Regular Training measure: Change from Baseline in Strength at 8 weeks measure: Change from Baseline in Endurance at 8 weeks measure: Change from Baseline in Agility at 8 weeks measure: Change from Baseline in Wrestling Performance at 8 weeks sex: ALL minimumAge: 10 Years maximumAge: 15 Years stdAges: CHILD facility: Batipark Sports Hall status: RECRUITING city: Kahramanmaraş zip: 46050 country: Turkey name: Talha Gökçe, PT role: CONTACT phone: +905065624802 email: talhagokce89@gmail.com lat: 37.5847 lon: 36.92641 hasResults: False
nctId: NCT06372795 id: KY2023635 briefTitle: Resistance Swallowing Training in Patients With Tracheotomy overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-05-01 date: 2026-12-31 date: 2024-04-18 date: 2024-04-18 name: Shanghai Zhongshan Hospital class: OTHER briefSummary: The goal of this clinical trial is to learn investigate the effect of instrument-assisted early progressive resistance swallowing training on swallowing related muscle strength in critically ill patients. It will also learn about the safety of swallowing training. The main questions it aims to answer are:
-Take instrument-assisted early progressive resistance swallowing training or pure effortful swallowing every day for 2 weeks and take muscle strength test every week. conditions: Swallowing Training on Muscle Strength studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 66 type: ESTIMATED name: pure effortful swallowing name: progressive resistance swallowing training measure: Forced swallowing tongue pressure sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06372782 id: 43CH2305 briefTitle: Comparing Pain, Safety and Effectiveness of Restylane Skinboosters Vital Lido and Vital Without Lido in Dorsal Hand overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-07 date: 2024-08 date: 2024-04-18 date: 2024-04-18 name: Galderma R&D class: INDUSTRY briefSummary: This is a randomized, multi-center, split-hand, subject-blinded study comparing pain, safety and effectiveness of Restylane Skinboosters Vital Lidocaine and Restylane Vital without lidocaine for improving appearance of the dorsal hands in Chinese subjects. conditions: Skin Aging of Dorsal Hands studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE whoMasked: PARTICIPANT count: 90 type: ESTIMATED name: Restylane Skinboosters Vital Lidocaine name: Restylane Vital measure: The within-subject difference in VAS score (Restylane Skinboosters Vital Lidocaine- Restylane Vital) at end of injection (T0). sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Galderma Research Site 01 city: Shanghai state: Shanghai country: China name: Principle Investigator role: CONTACT lat: 31.22222 lon: 121.45806 facility: Galderma Research Site 02 city: Hangzhou state: Zhejiang country: China name: Principle Investigator role: CONTACT lat: 30.29365 lon: 120.16142 facility: Galderma Research Site 03 city: Hangzhou state: Zhejiang country: China lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06372769 id: 20240304 briefTitle: Myoelectric Activity and Mandibular Movement for the Diagnosis of Temporomandibular Disorder overallStatus: COMPLETED date: 2022-02-01 date: 2022-07-15 date: 2023-02-10 date: 2024-04-18 date: 2024-04-18 name: Stomatological Hospital Affiliated with Fujian Medical University class: OTHER briefSummary: This study aimed to provide normal reference values of surface electromyography (sEMG) and mandibular kinematics in Chinese young adults, compare the sex differences and assess the diagnosis value of these indices. conditions: Temporomandibular Disorder studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 120 type: ACTUAL name: electromyograph and kinesiograph measure: Surface electromyography (μV) measure: Mandibular kinematics (mm, mm/s) sex: ALL minimumAge: 20 Years maximumAge: 35 Years stdAges: ADULT facility: The Affiliated Stomatological Hospital of Fujian Medical University city: Fuzhou state: Fujian zip: 350002 country: China lat: 26.06139 lon: 119.30611 hasResults: False
nctId: NCT06372756 id: 102122 briefTitle: Deep Learning Reconstruction Algorithms in Dual Low-dose CTA overallStatus: RECRUITING date: 2023-06-01 date: 2025-12 date: 2026-03 date: 2024-04-18 date: 2024-04-18 name: Hao Tang class: OTHER briefSummary: The goal of this observational study is to evaluate the impact of deep learning image reconstruction on the image quality and diagnostic performance of double low-dose CTA. The main question it aims to answer is to explore the feasibility of deep learning image reconstruction in double low-dose CTA. conditions: Deep Learning studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1200 type: ESTIMATED name: Deep learning image reconstruction measure: The specificity and sensitivity calculated through the optimal cutoff value of the receiver operating characteristic curve. measure: The signal-to-noise ratio calculated from image CT values and noise sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology status: RECRUITING city: Wuhan state: Hubei zip: 430000 country: China name: Youfa M Tang role: CONTACT phone: +8613554101223 email: 1525573397@qq.com lat: 30.58333 lon: 114.26667 hasResults: False
nctId: NCT06372743 id: Alex Hospital briefTitle: Nurse-led Physician-supported Care for Patients With Chronic Kidney Disease and Multimorbidity acronym: INTEGREATCKD overallStatus: RECRUITING date: 2023-11-01 date: 2025-05-31 date: 2026-12-31 date: 2024-04-18 date: 2024-04-18 name: Alexandra Hospital class: OTHER name: National University Hospital, Singapore briefSummary: Chronic kidney disease (CKD) is a prevalent chronic disease and is often intertwined with the management of cardiovascular disease and the optimization of metabolic risk factors. In light of steeply rising rates of end-stage kidney disease (ESKD) and increased healthcare resource utilization by CKD patients, the investigators propose that the role of nurses could be expanded to support the care of CKD patients in the community.
A total of 220 patients will be randomized (1:1) to the intervention or control groups (usual care). The intervention entails enrolment into a nurse-led, physician-supported programme (INTEGREAT-CKD), comprising outpatient consultations and community-based ambulatory monitoring and counselling primarily driven by CKD-trained advanced practice nurses (APNs) and healthcare professionals conducted over 6 months. Patient-reported outcomes like health-related quality of life (HRQOL), as measured by EQ-5D and KDQOL, CKD self-management score and CKD health literacy will be assessed at baseline and after 6 months. The primary outcome is CKD self-management. Other secondary outcomes to be assessed and tracked including achievement of clinical targets relevant to slowing down CKD progression, attainment of CKD best practice guidelines as specified in the KDIGO CKD Evaluation and Management guidelines 2020. conditions: Chronic Kidney Diseases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This study is a dual-centre two-arm, open-label randomized controlled trial (RCT). Patients are randomized with a one-to-one allocation into two parallel groups. primaryPurpose: TREATMENT masking: NONE count: 220 type: ESTIMATED name: INTEGREAT-CKD Intervention measure: Chronic Kidney Disease Self-Management (CKD-SM) Questionnaire measure: Secondary outcome sex: ALL minimumAge: 21 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Wei Zhen Hong status: RECRUITING city: Singapore zip: 119228 country: Singapore name: Wei Zhen Hong role: CONTACT phone: 97330789 email: wei_zhen_hong@nuhs.edu.sg name: Priyanka Khatri, MBBS role: SUB_INVESTIGATOR lat: 1.28967 lon: 103.85007 hasResults: False
nctId: NCT06372730 id: 29BRC23.0161 id: 2023-A01566-39 type: OTHER domain: IDRCB briefTitle: Residual Pulmonary Vascular Obstruction Index Computed With Ventilation/Perfusion SPECT/CT Imaging to Predict the Risk of Venous Thromboembolism Recurrence in Patients With Pulmonary Embolism (PRONOSPECT) acronym: PRONOSPECT overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2028-10 date: 2029-01 date: 2024-04-18 date: 2024-04-18 name: University Hospital, Brest class: OTHER briefSummary: Major risk after pulmonary embolism (PE) is recurrence, fatal in 10% of patients. Patients with PE can be stratified in 3 groups according to the risk of recurrence : very low risk, high risk or Intermediate risk. Little is known about this last group.
nctId: NCT06372717 id: AP30CP01 briefTitle: A Study to Investigate APL-4098 Alone and/or in Combination With Azacitidine in R/R AML and High-Risk MDS overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2027-03-01 date: 2027-04-01 date: 2024-04-18 date: 2024-04-18 name: Apollo Therapeutics Ltd class: INDUSTRY briefSummary: This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-4098 alone and/or in combination with azacitidine for the treatment of relapsed or refractory (R/R) acute myeloid leukemia (AML), myelodysplastic syndrome (MDS)/AML and MDS-excess blasts (EB). Participants with the MDS-EB subtype will be eligible for the Phase 1 part of the study only. conditions: Acute Myeloid Leukemia Refractory conditions: Myelodysplastic Syndrome Acute Myeloid Leukemia conditions: Myelodysplastic Syndrome With Excess Blasts conditions: Acute Myeloid Leukemia, in Relapse studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 112 type: ESTIMATED name: APL-4098 name: Azacitidine and APL-4098 measure: Incidence of Treatment Emergent Adverse Events [Safety] (Phase 1) measure: Incidence of Dose Limiting Toxicities [Tolerability] (Phase 1) measure: Estimate the Maximum Tolerated Dose (MTD) of APL-4098 alone and/or in combination with azacitidine (Phase 1) measure: Determine Recommended Phase 2 Dose (RP2D) levels of APL-4098 alone and/or in combination with azacitidine (Phase 1) measure: Assess the Pharmacokinetics of APL-4098 alone and/or in combination with azacitidine (Phase 1) measure: Assess the Pharmacokinetics of APL-4098 alone and/or in combination with azacitidine (Phase 1) measure: Assess the Pharmacokinetics of APL-4098 alone and/or in combination with azacitidine (Phase 1) measure: Assess efficacy of APL-4098 alone and/or in combination with azacitidine (Phase 2) measure: Assess response to disease with APL-4098 alone and/or in combination with azacitidine (Phase 1) measure: Duration of response with APL-4098 alone and/or in combination with azacitidine [Further efficacy] (Phase 2) measure: Time to response with APL-4098 alone and/or in combination with azacitidine [Further efficacy] (Phase 2) measure: Event Free Survival with APL-4098 alone and/or in combination with azacitidine [Further efficacy] (Phase 2) measure: Overall Survival with APL-4098 alone and/or in combination with azacitidine [Further efficacy] (Phase 2) measure: Incidence of Treatment Emergent Adverse Events [Further Safety] (Phase 2) measure: Incidence of Adverse Events leading to discontinuation of APL-4098 [Further Tolerability] (Phase 2) measure: Further assess the PK of APL-4098 alone and/or in combination with azacitidine (Phase 2) measure: Further assess the PK of APL-4098 alone and/or in combination with azacitidine (Phase 2) measure: Further assess the PK of APL-4098 alone and/or in combination with azacitidine (Phase 2) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06372704 id: 2024/72 briefTitle: Is the HIFEM Procedure an Effective Treatment for Men With Post-prostatectomy Incontinence? acronym: HIFEM for PPI overallStatus: COMPLETED date: 2024-02-01 date: 2024-04-01 date: 2024-04-05 date: 2024-04-18 date: 2024-04-24 name: Kirsehir Ahi Evran Universitesi class: OTHER briefSummary: Urinary incontinence after radical prostatectomy surgery is a common condition that negatively affects daily life. Patients often experience discomfort due to urine leakage and the resulting need to use pads daily. This study aimed to evaluate the efficacy and safety of high-intensity focused electromagnetic technology used therapeutically in patients with urinary incontinence after radical prostatectomy. conditions: Prostate Cancer conditions: Incontinence conditions: Pelvic Floor Muscle Weakness studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 27 type: ACTUAL name: HIFEM measure: This study demonstrated the safe and effective use of HIFEM technology to prevent PPI by strengthening the pelvic floor muscles in a variety of patients. sex: MALE minimumAge: 63 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: İbrahim Üntan city: Kirşehi̇r country: Turkey lat: 39.14583 lon: 34.16389 hasResults: False
nctId: NCT06372691 id: PoplitealApproach SciaticBlock briefTitle: How Do We Ultrasound-Guided Popliteal Approach Sciatic Nerve Block? overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-08-01 date: 2024-09-01 date: 2024-04-18 date: 2024-04-18 name: Ankara City Hospital Bilkent class: OTHER briefSummary: The aim of this prospective, randomized, observer-blind study to compare subparaneural approach injection with interneural approach injection in popliteal sciatic nerve blocks. conditions: Adult conditions: Regional Anesthesia Morbidity conditions: Anesthesia Injection Site studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: OTHER masking: NONE count: 809 type: ESTIMATED name: Subparaneural Injection (Grup S), Block name: Interneural Injection (Grup I), Block measure: Onset Time measure: Block Execution Times measure: Need for Multiple Injections Owing to Insufficient Anesthesia measure: Additional Rescue Analgesic measure: Adverse Effects to Anesthesia measure: Hemodynamic Effects Of The Block measure: Effects Of The Block On Heart Rate measure: Effects Of The Block On Peripheral Pulse Oximetry measure: Regression Time Of Sensory and Motor Block measure: Total Block Times sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06372678 id: CM326-102102 briefTitle: Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis overallStatus: NOT_YET_RECRUITING date: 2024-06-30 date: 2026-06-30 date: 2026-06-30 date: 2024-04-18 date: 2024-04-18 name: Keymed Biosciences Co.Ltd class: INDUSTRY briefSummary: This is a multi-center, randomized, double blind, placebo-controlled Phase II study to evaluate the efficacy and safety of CM326, and to observe the Pharmacokinetics, Pharmacodynamics and immumogenicity of CM326 in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). conditions: Chronic Rhinosinusitis With Nasal Polyps studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 90 type: ESTIMATED name: CM326 name: Placebo measure: Changes from baseline of nasal polyp score (NPS) in eosinophilic chronic rhinosinusitis with nasal polyps (CRSwNP) at week 24. sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Tongren Hospital, CMU city: Beijing state: Beijing country: China lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06372665 id: CDB-IV-JE-025202301 briefTitle: Safety Observation of the Japanese Encephalitis Vaccine Given With a Primary Immunization overallStatus: RECRUITING date: 2024-01-01 date: 2025-03-31 date: 2025-06-30 date: 2024-04-18 date: 2024-04-18 name: Liaoning Chengda Biotechnology CO., LTD class: INDUSTRY briefSummary: This is a single-arm, non-randomized, open-label post-marketing safety observation study. The purpose of this study is to investigate the safety of JEV-I given with primary immunization in a large amount of healthy children aged 8 months and older. conditions: Japanese Encephalitis studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 28547 type: ESTIMATED measure: Number of Participants Reporting Solicited Local and Systemic Adverse Events, and Unsolicited Adverse Events sex: ALL minimumAge: 8 Months stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Jiangsu Provincial Center for Disease Control and Prevention status: RECRUITING city: Nanjing state: Jiangsu zip: 210009 country: China name: Zhiguo Wang, Master role: CONTACT email: 120714991@QQ.com name: Zhiguo Wang, Master role: PRINCIPAL_INVESTIGATOR lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06372652 id: TE-8214-001 briefTitle: A Phase 1 Study of TE-8214 Solution in Healthy Volunteers overallStatus: NOT_YET_RECRUITING date: 2024-05-02 date: 2024-10-10 date: 2024-12-26 date: 2024-04-18 date: 2024-04-19 name: Immunwork, Inc. class: INDUSTRY briefSummary: This is a Phase 1, first-in-human, randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, and PK of TE-8214 in healthy volunteers. The study will assess single ascending doses (SAD) of TE-8214. conditions: Acromegaly studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 32 type: ESTIMATED name: TE-8214 - SAD name: Placebo measure: Safety and tolerability of TE-8214 by the incidence of treatment-emergent adverse events (TEAEs) measure: Safety and tolerability of TE-8214 by the incidence of treatment-related adverse events measure: Safety and tolerability of TE-8214 by the incidence of injection site reactions (ISRs) measure: Safety and tolerability of TE-8214 by the incidence of clinically significant laboratory findings measure: Safety and tolerability of TE-8214 by the changes in physical examination findings measure: Safety and tolerability of TE-8214 by the changes in ECG findings measure: PK Parameters: Maximum observed concentration (Cmax) measure: PK Parameters: Time to maximum observed concentration (Tmax) measure: PK Parameters: Area under the concentration-time curve (AUC) from time zero to the last measurable concentration (AUC 0-last) sex: ALL minimumAge: 18 Years maximumAge: 64 Years stdAges: ADULT facility: CMAX Clinical Research city: Adelaide state: South Australia zip: 5000 country: Australia name: Jessica Gehlert, Dr role: CONTACT lat: -34.92866 lon: 138.59863 hasResults: False
nctId: NCT06372639 id: TAU-PTSD-TMS briefTitle: Characterization and Modulation of Traumatic Memories in PTSD Patients Using TMS overallStatus: RECRUITING date: 2022-02-23 date: 2024-11-24 date: 2024-11-24 date: 2024-04-18 date: 2024-04-18 name: Tel Aviv University class: OTHER briefSummary: Characterization and modulation of traumatic memories in PTSD patients using TMS. conditions: Post Traumatic Stress Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Trans-Cranial Magnetic Stimulation measure: CAPS-5 score measure: Neurological measures of functional connectivity measure: Intrusive memories sex: ALL minimumAge: 20 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tel Aviv University status: RECRUITING city: Tel Aviv zip: 69978 country: Israel name: Yair Bar-Haim, PhD role: PRINCIPAL_INVESTIGATOR lat: 32.08088 lon: 34.78057 hasResults: False
nctId: NCT06372626 id: ZG005-004 briefTitle: Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2026-07 date: 2026-08 date: 2024-04-18 date: 2024-04-18 name: Suzhou Zelgen Biopharmaceuticals Co.,Ltd class: INDUSTRY briefSummary: The trial is divided into two parts. PART 1 is a dose escalation study of the ZG005 combined with Etoposide and Cisplatin, primarily assessing the tolerability and safety of this combined treatment. PART 2 is a dose expansion study, further evaluating the preliminary efficacy and safety of this combined treatment. conditions: Neuroendocrine Carcinoma studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 93 type: ESTIMATED name: ZG005 name: Etoposide name: Cisplatin name: Placebo measure: Dose Limiting Toxicity (DLT) measure: Objective Response Rate (ORR) measure: Adverse Event (AE) sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chinese PLA General Hospital city: Beijing state: Beijing zip: 100853 country: China name: Jianming Xu role: CONTACT lat: 39.9075 lon: 116.39723 hasResults: False